drugset / Trial / NCT00324129
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with leukemia or myelodysplastic syndromes.
Timeline
- Start
- 2005-02
- Primary completion
- 2006-07
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mocetinostat | Small molecule | — | Oral |